warfarin and Hepatorenal-Syndrome

Although warfarin remains important despite the widespread use of nonvitamin K antagonist oral anticoagulants (NOACs), to date, the reality of warfarin use in the "NOACs era" is unclear. This multicenter observational study aimed to clarify the key factors contributing to warfarin treatment stability.. The practical use of warfarin, stability of warfarin therapy, and factors contributing to this stability were investigated in community-based hospitals through a real-world study. Clinical data were retrospectively extracted from the medical records of warfarin-treated Japanese patients (age, 71.3±5.5 years) with atrial fibrillation (AF), prosthetic heart valve, or other concerns requiring anticoagulation. Treatment stability was considered as time in therapeutic range of international normalized ratio of prothrombin time (TTR: %). The factors contributing to TTR were investigated, including CHADS. Mean CHADS. This retrospective study demonstrated that the CHADS

Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Coagulation; Cardiovascular Diseases; Echocardiography; Female; Hepatorenal Syndrome; Humans; Kidney Function Tests; Liver Function Tests; Magnetic Resonance Imaging; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed; Warfarin